Abstract
Background: Topical delivery of therapeutic agents is considered beneficial due to various advantages like ease of administration, avoidance of the first-pass effect, and improved patient compliance. Therefore, scientists around the globe are exploring this route for the delivery of drugs nowadays.
Objective: The present patent investigation aimed to prepare, optimize, and characterize the urealoaded microsponges for efficient topical delivery in vitro.
Methods: Urea-loaded ethylcellulose microsponges were prepared using quasi emulsion solvent diffusion technique and optimized using Box–Behnken design (BBD). Furthermore, they were characterized in-vitro using various techniques like scanning electron microscopy (SEM), differential scanning calorimetry (DSC), Fourier-transform infrared spectroscopy (FT-IR), and X-ray diffraction analysis (XRD). In-vitro drug release and release kinetics analysis was also performed.
Results: Urea-loaded microsponges were spherical and porous. Optimized urea loaded microsponges showed a minimum size (39.78 ± 1.98 μm), high entrapment (74.56 ± 2.8%), acceptable polydispersity index (PDI) (0.224 ± 0.081) and zeta potential (-21.9 ± 2.9 mV). These microsponges were capable of sustaining the release of urea for 24 h (91.21 ± 5.20%), and the mechanism of release was the combination of diffusion and erosion.
Conclusion: The developed microsponge system could be beneficial for topical delivery of urea as it could reduce the dosing frequency of urea and increase patient compliance through its sustained release.
Keywords: Box–Behnken design (BBD), dosing frequency, ethylcellulose, microsponges, patient compliance, sustained release, urea.
Graphical Abstract
[http://dx.doi.org/10.1111/dth.12690] [PMID: 30378232]
[http://dx.doi.org/10.1111/ijcp.13621] [PMID: 33249707]
[PMID: 27168272]
[http://dx.doi.org/10.1080/02652040600789328] [PMID: 17118885]
[http://dx.doi.org/10.1080/02652040802000714] [PMID: 18465299]
[http://dx.doi.org/10.3109/08982100903015025] [PMID: 19530897]
[http://dx.doi.org/10.1016/j.msec.2016.07.043] [PMID: 27612773]
[http://dx.doi.org/10.1155/2013/161943] [PMID: 24062995]
[http://dx.doi.org/10.3109/02652048.2011.604435] [PMID: 21824068]
[http://dx.doi.org/10.1080/02652048.2019.1667447] [PMID: 31509035]
[http://dx.doi.org/10.2478/v10007-011-0022-6] [PMID: 21945905]
[http://dx.doi.org/10.4103/0976-0105.177705] [PMID: 27057125]
[http://dx.doi.org/10.1016/j.ijpharm.2005.11.001] [PMID: 16359833]
[http://dx.doi.org/10.1155/2015/261068] [PMID: 25789176]
[http://dx.doi.org/10.3390/ma9110943] [PMID: 28774062]
[http://dx.doi.org/10.1016/j.apsusc.2017.02.146]
[http://dx.doi.org/10.1080/00387010.2012.728553]
[http://dx.doi.org/10.1016/j.optlastec.2019.03.034]
[http://dx.doi.org/10.2174/1872211308666140305222905] [PMID: 24548242]
[http://dx.doi.org/10.1002/ddr.21492] [PMID: 30456763]
[http://dx.doi.org/10.1007/s40204-018-0099-9] [PMID: 30242738]
[http://dx.doi.org/10.4172/pharmaceutical-sciences.1000459]
[http://dx.doi.org/10.1016/j.jddst.2015.09.006]
[http://dx.doi.org/10.3390/polym12122903] [PMID: 33287406]
[http://dx.doi.org/10.1208/s12249-009-9220-7] [PMID: 19381834]
[http://dx.doi.org/10.1016/j.ejps.2016.09.038] [PMID: 27697504]
[http://dx.doi.org/10.1016/S0014-827X(02)00007-1] [PMID: 12581775]
[http://dx.doi.org/10.1155/2014/340701] [PMID: 25093165]
[http://dx.doi.org/10.3390/pharmaceutics12030234] [PMID: 32151053]
[http://dx.doi.org/10.2174/2211738506666180813122102] [PMID: 30101725]
[http://dx.doi.org/10.1155/2014/904036] [PMID: 26556206]
[http://dx.doi.org/10.4103/0250-474X.62251] [PMID: 20582193]
[http://dx.doi.org/10.1016/j.ijbiomac.2020.07.168] [PMID: 32698069]
[http://dx.doi.org/10.2147/IJN.S166413] [PMID: 30127605]
[http://dx.doi.org/10.3109/10837450.2013.778874] [PMID: 23560821]
[http://dx.doi.org/10.1515/gps-2020-0015]
[http://dx.doi.org/10.2174/1876402912999200831105145]
[http://dx.doi.org/10.1016/j.molliq.2020.112633]
[http://dx.doi.org/10.3329/dujps.v9i2.7883]
[http://dx.doi.org/10.3797/scipharm.0908-09] [PMID: 21179372]